Effects of third generation oral contraceptives containing newly developed progestagens on fibrinolytic parameters

Fibrinolysis and Proteolysis

Volumn 11, Issue 2, 1997, Pages 97-101

  Quehenberger, P ^a,b   Loner, U ^a,b   Kapiotis, S ^a,b   Handler, S ^a,b   Schneider, B ^a,b   Huber, J ^a,b   Speiser, W ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; GESTAGEN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION;

EID: 0030660394     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80101-4     Document Type: Article

References (35)

1. Royal College of General Practitioners. Oral contraception and thromboembolic disease. J R Coll Gen Pract 1967; 13: 267-279.
2. Vessey M P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2: 199-205.
3. Sartwell P E, Masi A T, Arthes F G, Greene G R, Smith H E. Thromboembolism and oral contraceptives: an epidemiological case control study. Am J Epidemiol 1969; 90: 365-380.
4. Stadel B V. Oral contraceptives and cardiovascular disease. N EnglJMed 1981; 305: 612-618.
5. Sartwell P E, Stolley P D. Oral contraceptives and vascular disease. Epidemiol Rev 1982; 4: 95-109.
6. Croft P, Hannaford P C. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. Br Med J 1989; 298: 165-168.
7. La Vecchia C, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987; 125: 832-843.
8. Mettinger K L, Soderstorm C D, Weiman J. Stroke before 55 years of age at Karolinska hospital 1973-1977: study of 399 well-defined cases. Acta Neurol Scand 1984; 70: 415-422.
9. Stolley P D, Storm B L, Sartwell P E. Oral contraceptives and vascular disease. Epidem Rev 1989; 11: 241-243.
10. Abbate R, Pinto S, Rostagno C, Bruni V, Rosati D, Mariani G. Effects of long-term gestodene-containing oral contraceptive administration on hemostasis. Am J Obstet Gynecol 1990; 163: 424-430.
11. Gram J, Munkvad S, Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am J Obstet Gynecol 1990; 163: 438-442.
12. Quehenberger P, Lohner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996; 76: 729-734.
13. Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol 1992; 2: 439-443.
14. Mammen E F. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781-790.
15. Meade T W. Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol 1982; 142: 758-761.
16. Daly L, BonnarJ. Comparative study of 30 μg ethinylestradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. AmJ Obstet Gynecol 1990; 163: 430-437.
17. Poller M. Oral contraceptives, blood clotting and thrombosis. Br Med Bull 1978; 34: 151-156.
18. Malm J, Laurel! M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraceptives. Br J Haematol 1988; 68:437-443.
19. Boerger L M, Morris ? C, Thurnau G R, Esmon C T, Comp P C. Oral contraceptives and gender affect protein S status. Blood 1987; 69: 692-694.
20. Kooistra T, Bosma P J, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-412.
21. Jespersen J, PetersenKR, Skouby O. Effects of ne wer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163:396-403.
22. David J L, Gaspard U J, Gillain D, Raskinet R, Lepot M R. Hemostasis profile in women taking low-dose oral contraceptives. Am J Obstst Gynecol 1990; 163: 420-423.
23. Petersen K R, Sidelmann J, Skouby S O, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993; 168:32-38.
24. Campbell S J, Mackie IJ, Robinson G E, Machin S J. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Brit J Obstet Gynecol 1993; 100: 79-84.
25. Quehenberger P, Kapiotis S, Pärtan C, Schneider B, Wenzel R, Gaiger A, Speiser W. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol 1993; 67: 33-36.
26. Bloemenkamp K W M, Rosendaal F R, Heimerhorst F M, Büller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
27. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582.
28. Jick H, Jick S S, Gurewich V, Wald Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
29. 2-macroglobulin-plasmin complexes in plasma. J Clin Invest 1981 ; 68: 46-55.
30. Elms M J, Bunce I H, Bundesen P G, Rylatt D B, Webber A J, Masci P P, Whitaker A N. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50: 591- 594.
31. Gaffney P J, Longstaff C. An overview of fibrinolysis. In: Bloom AL, Forbes C D, Thomas D P, Tuddenham E G D, eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994: 549-573.
32. Moroi M, Aoki N. Isolation and characterization of (cc2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965.
33. Hoylaerts M, Rijken D C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257:29122917.
34. Speiser W, Anders E, Binder B R, Müller-Bergbaus G. Clot lysis mediated by cultured human microvascular endothelial cells. Thromb Haemost 1988; 60: 463-467.
35. Vandenbrouke J P, Koster T, Briet E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.